## Synodos for NF2

[consortiapedia.fastercures.org](consortiapedia.fastercures.org)

### Research Areas

<table>
<thead>
<tr>
<th>Area</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Tool Development</strong></td>
<td>Clinical Trial</td>
</tr>
<tr>
<td><strong>Biomarker Research</strong></td>
<td>Drug</td>
</tr>
<tr>
<td><strong>Data-Sharing Enabler</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Drug Development</strong></td>
<td>Drugs</td>
</tr>
</tbody>
</table>

### At a Glance

- **Status:** Active Consortium
- **Year Launched:** 2016
- **Initiating Organization:** Children’s Tumor Foundation
- **Initiator Type:** Nonprofit foundation
- **Rare disease**
- **Location:** North America

### Abstract

Neurofibromatosis Type 2 (NF2) is characterized by tumors that develop throughout the central and peripheral nervous system. Though NF2 tumors are benign, these patients experience significant morbidity and mortality because of the location of the tumors, their compressive effects, and the effects of current treatments. Synodos for NF2 is a $3 million, multi-year initiative that has assembled a team of researchers from twelve world-class labs and medical centers. This comprehensive, collaborative model brought together experts in basic, translational, and clinical research, who have joined forces to share information, free of bureaucratic obstacles and institutional competition.

### Mission

The goal of Synodos for NF2 is to discover novel therapeutic agents for clinical treatment, that either successfully shrink NF2 tumor types, or halt tumor growth without long-term toxicity, or with a
manageable long-term toxicity profile. Synodos for NF2 aims to deliver multiple new and advanced cell and animal models to accelerate drug screening, new target pathways, and an increased understanding of response and resistance to treatment. Eventually this work will result in new clinical trials for NF2, and effective combination therapies.

**Consortium History**

Synodos was born from the Children’s Tumor Foundation’s dissatisfaction with the scientific research process. It models an approach that promotes data sharing and collaboration rather than data hoarding and competition so as to more efficiently and quickly accelerate the cancer research process.

**Structure & Governance**

Developed by the Children’s Tumor Foundation

**Financing**

Funded by the Children’s Tumor Foundation

**Patent Engagement**

The consortium recruits patients for testing of clinical trials

**Links/Social Media Feed**
Points of Contact

Salvatore La Rosa, PhD
slarosa@ctf.org
120 Wall Street, 16th Floor
New York, NY 10005

Sponsors & Partners

Children’s Tumor Foundation
Washington University
German Cancer Research Center
University of California SF
Children’s Hospital of Philadelphia
University of Minnesota
Cincinnati Children’s Hospital
National Cancer Institute
Recombinetics, Inc.
University of Iowa
Sanford School of Medicine
Exempler Genetics
University of Florence
University of Toronto

Updated: 06/27/2017